Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Acute Bacterial Skin And Skin Structure Infections Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The acute bacterial skin and skin structure infections market has experienced significant expansion in recent years. Its value is projected to rise from $12.9 billion in 2025 to $14.09 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.2%. The growth observed in prior periods can be attributed to several factors, including the limited availability of broad-spectrum antibiotics, an increase in the prevalence of hospital-acquired infections, greater awareness of complications from skin infections, improved access to community healthcare, and the widespread adoption of standard infection control protocols.
The market size for acute bacterial skin and skin structure infections is anticipated to expand significantly in the coming years. It is projected to achieve a valuation of $20.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. This growth during the forecast period is primarily driven by factors such as the advancement of next-generation antibiotics, increased investments in antimicrobial research, the expansion of community-based infection management programs, the broadening of hospital pharmacy distribution channels, and the adoption of rapid diagnostic technologies. Notable trends during this period include a rising prevalence of acute bacterial skin and skin structure infections, an increasing embrace of novel antibiotics and combination therapies, the growth of hospital and community healthcare facilities, a greater reliance on oral and parenteral antibiotics, and a dedicated focus on lowering hospital-acquired infection rates.
Get A Free Sample Report With In-Depth Market Insights:
Acute Bacterial Skin And Skin Structure Infections Market Growth Drivers: What’s Behind The Acceleration?
The increasing occurrence of skin infections is anticipated to fuel the expansion of the acute bacterial skin and skin structure infections market moving forward. Skin infections are conditions where microorganisms, such as bacteria, fungi, or viruses, invade and multiply within the skin, leading to various symptoms and discomfort. This surge in skin infections drives a greater need for therapeutic solutions, antibiotics, and innovative treatments to tackle acute bacterial and skin structure infections, ensuring patients receive the best possible care and outcomes. For instance, in March 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that about 1.8 billion people globally suffer from skin conditions at any time. Neglected tropical diseases (NTDs) comprise around 10% of these cases, with fungal infections at 34% and bacterial infections at 23%, frequently leading to high mortality rates. Thus, the growing prevalence of skin infections will propel the growth of the acute bacterial skin and skin structure infections market.
Acute Bacterial Skin And Skin Structure Infections Market Segment Breakdown: Which Categories Lead On Revenue?
The acute bacterial skin and skin structure infections market covered in this report is segmented –
1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections
2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Infections Related To Medical Devices
2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections
Acute Bacterial Skin And Skin Structure Infections Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the acute bacterial skin and skin structure infections market are concentrating on developing innovative single-dose therapies, such as Dalbonova, to gain a competitive advantage. Dalbonova is a single-dose treatment that provides convenience and effectiveness, enabling patients to achieve desired results with just one potent 1500 mg dose administered once. For example, in August 2023, BDR Pharmaceuticals International Pvt. Ltd., an India-based pharmaceutical company specializing in API and formulation therapeutic segments, including acute bacterial skin and skin structure infections, introduced Dalbonova injection, a single-dose therapy for acute bacterial skin and skin structure infections (ABSSSI). Dalbonova Injection lessens the risk of hospital-acquired diseases by offering a single-dose treatment and removing the need for hospital admissions. It is formulated to treat acute bacterial skin and skin structure infections (ABSSSI) caused by certain gram-positive microorganisms in patients of all ages, including newborns.
Acute Bacterial Skin And Skin Structure Infections Market Leading Players And Competitive Positioning
Major companies operating in the acute bacterial skin and skin structure infections market are Pfizer Inc., AbbVie Inc., Novartis AG, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Aspen Pharmacare Holdings Limited, Melinta Therapeutics LLC, Abbott Laboratories, Fresenius SE & Co. KGaA, Menarini Group
View The Full Acute Bacterial Skin And Skin Structure Infections Market Report:
Acute Bacterial Skin And Skin Structure Infections Market Top Region By Revenue And Market Share
Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.